Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Demonstrable hypertension defined as mean sitting trough cuff blood pressure ≥ 140/100 mmHg (SeSBP ≥ 140 mmHg and SeDBP ≥ 100mmHg) or mean sitting trough cuff BP ≥ 160/90 mmHg (SeSBP ≥ 160 mmHg and SeDBP ≥ 90mmHg).~* Male or female newly diagnosed hypertensive subjects or currently on hypertension medication.~  * Negative urine pregnancy test at screening~ * Not lactating~ * Do not plan to become pregnant during the study~ * Will practice birth control throughout the study by the following: oral or patch contraceptive, injectable or implantable contraceptive medication, intrauterine device, diaphragm or female condom plus spermicide~    * Non childbearing potential must be classified by one of the following criteria~   * Had a hysterectomy or tubal ligation at least 6 months prior to consent~   * Has been postmenopausal for a least 1 year~Exclusion Criteria:~* Mean sitting trough cuff DBP \<90 mmHg or mean sitting trough cuff SBP \<140 mmHg (off antihypertensive medication).~* Subjects with uncontrolled hypertension taking multiple antihypertensive therapies (at the discretion of the investigator).~* Signs or symptoms which could exacerbate the occurrence of hypotension such as volume and salt depletion.~* History of hypertensive encephalopathy, stroke or transient ischemic attack (TIA).~* Participation in another clinical trial involving an investigational drug within one month prior to screening.~* History of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina within the past 6 months.~* Any history of New York Heart Association Class III or IV congestive heart failure (CHF). A history of New York Heart Association Class I or II CHF may be exclusionary at the discretion of the investigator.~* History of secondary hypertension including renal disease, pheochromocytoma, or Cushing's syndrome.~* Uncorrected coarctation of the aorta, bilateral renal artery stenosis, or unilateral renal artery stenosis in a solitary kidney.~* Evidence of symptomatic resting bradycardia.~* Evidence of hemodynamically significant cardiac valvular disease.~* Presence of heart block greater than first degree atrioventricular block, chronic atrial fibrillation or flutter.~* Uncontrolled Type I or Type II diabetes defined as HbA1c \>9.0%. Diabetics must have documentation of HbA1c within 6 months of the Screening Visit. Undocumented subjects must have their HbA1c assessed prior to randomization. Note: Subjects with Type I or Type II diabetes controlled with insulin, diet or oral hypoglycemic agents on a stable dose for at least 30 days may be included.~* Evidence of liver disease as indicated by ALT and AST and/or total bilirubin \>3 times the upper limit of normal.~* Severe renal insufficiency defined as a creatinine clearance (based on the Cockcroft-Gault formula) of \<30 mL/min.~* Clinically significant laboratory elevations at Visit 1 that compromise subject safety, based on the investigator's judgment. Consideration should take into account the potential laboratory effects of the component blinded therapies.~* Positive for any one of the following tests: hepatitis B surface antigen, hepatitis C antibody (confirmed by radio immunobinding assay, RIBA) or HIV antibody (confirmed by western blot assay).~* Subjects with malignancy during the past 2 years excluding squamous cell or basal cell carcinoma of the skin.~* Known allergy to any of the medications used in the study.~* Subjects who require or are taking any concomitant medication, which may interfere with the objectives of the study (Refer to Section 5.2 for a listing of excluded medications).~* Pregnant or lactating females.~* Current history of drug or alcohol abuse.~* A subject with any medical condition, which in the judgment of the Investigator would jeopardize the evaluation of efficacy or safety and/or constitute a significant safety risk to the subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- OM40/AML10 (Type: EXPERIMENTAL): olmesartan medoxomil 40mg and amlodipine 10mg
- OM40/HCTZ25 (Type: ACTIVE_COMPARATOR): olmesartan medoxomil 40mg and hydrochlorothiazide 25mg
- AML10/HCTZ25 (Type: ACTIVE_COMPARATOR): amlodipine 10mg and hydrochlorothiazide 25mg
- OM40/AML10/HCTZ25 (Type: ACTIVE_COMPARATOR): olmesartan medoxomil 40mg, amlodipine 10mg, and hydrochlorothiazide 25mg

Based on this trial design, predict the completion outcome and termination type (if applicable).